Q32 Bio Resets As A Public Company With Two Mid-Stage Assets

 
• By Jessica Merrill

The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.

stock market
Q32 Bio is going public through a reverse merger • Source: Shutterstock

More from Financing

More from Business